Form 4: Caris Life Sciences CFO Sells Shares After Option Exercise
Insider Transaction Report
Caris Life Sciences' CFO, Luke Thomas Power, exercised stock options and subsequently sold a significant number of common shares on December 11, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Luke Thomas Power, Senior Vice President, Chief Financial Officer, and Chief Accounting Officer of Caris Life Sciences, Inc., reported transactions on December 11, 2025.
- These transactions included the exercise of 24,750 stock options and 37,500 stock options, both at an exercise price of $2.44 per share.
- Following the option exercises, Power sold 60,850 shares of common stock at a weighted average price of $26.5644 and an additional 1,400 shares at a weighted average price of $27.1554.
- All reported transactions were conducted under a Rule 10b5-1 trading plan adopted on August 19, 2025.
- After these transactions, Power's direct beneficial ownership of Caris Life Sciences, Inc. common stock stands at 99,571 shares.
Sentiment
Score: 5
Explanation: The filing reports pre-planned insider transactions (option exercise and sale) by a CFO. While the sale of shares by an executive can sometimes be viewed negatively, the execution under a Rule 10b5-1 plan mitigates concerns about opportunistic timing, making the sentiment neutral.
Positives
- The transactions were executed pursuant to a Rule 10b5-1 trading plan, indicating pre-planned sales and mitigating concerns about opportunistic trading based on undisclosed information.
Negatives
- A significant sale of shares by a high-ranking executive (CFO) could be perceived negatively by some investors, potentially signaling a belief that the stock price may not rise significantly in the near term.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may interpret the sale as a lack of strong conviction in future stock price appreciation, though the 10b5-1 plan suggests it is not based on new, undisclosed information.
Key Dates
| Date | Description |
|---|---|
| 08/19/2025 | Date Rule 10b5-1 trading plan was adopted by the reporting person. |
| 12/11/2025 | Date of stock option exercises and common stock sales. |
| 12/12/2025 | Signature date of the reporting person's attorney-in-fact. |
| 05/30/2027 | Expiration date for 24,750 stock options. |
| 11/14/2028 | Expiration date for 37,500 stock options. |
Recommendation
holdThe filing details a pre-planned sale of shares by the CFO following option exercises. While insider selling can sometimes be a bearish signal, the execution under a Rule 10b5-1 plan suggests the decision was made in advance and not based on new, material non-public information. Without additional context on the company's performance or strategic direction, this transaction alone does not warrant a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate as investors should await further company updates.
Keywords
Caris Life Sciences, CAI, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Luke Thomas Power, CFO, 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.